RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oryzon Genomics Stock

Oryzon Genomics Market capitalization 2024

Oryzon Genomics Market capitalization

116.16 M EUR

Ticker

ORY.MC

ISIN

ES0167733015

WKN

A2ACV2

In 2024, Oryzon Genomics's market cap stood at 116.16 M EUR, a -6.79% increase from the 124.62 M EUR market cap in the previous year.

The Oryzon Genomics Market capitalization history

YEARMarket Capitalization (undefined EUR)
2023132.62
2022137.22
2021183.97
2020156.07
2019145.7
2018121.02
201799.48
201689.66
2015101.88
2014-
2013-
2012-

Oryzon Genomics Aktienanalyse

What does Oryzon Genomics do?

The company Oryzon Genomics SA is a biopharmaceutical company that was founded in 2000 in Barcelona, Spain. Since then, the company has gained a growing reputation for the development of innovative therapeutic approaches for serious diseases. Oryzon works on the development of epigenetic products that focus on molecular docking sites in the cell to modulate approved proteins and fragments. They use a unique technology called ORY-1001 to promote tumor apoptosis. The technology involves the use of epigenetic modulators to develop therapeutic approaches for certain types of cancer such as CLL and leukemia. Oryzon operates various divisions such as Research and Development, Intellectual Property, and Product Development. Within Research and Development, they work on the research and development of new technologies and products. They also have a portfolio of patented and potential patent applications in the field of epigenetics and products for the treatment of various types of cancer, neurodegenerative diseases such as Alzheimer's, and schizophrenia. The Intellectual Property division is responsible for all of Oryzon's patent rights. They review all of Oryzon's patents to ensure they meet the highest standards of patent law. The Product Development department helps the company in transferring newly developed products into effective and approved drugs. They also assist in the approval process by health authorities, particularly in the field of clinical trials. At the beginning of 2020, Oryzon announced that they will start a Phase 2 clinical trial for their product line ORY-2001 for the treatment of Alzheimer's patients. ORY-2001 is a selective histone deacetylase (HDAC) inhibitor aimed at slowing down the pathological process of Alzheimer's and other neurodegenerative diseases. This technology has the potential to improve the lives of millions of patients worldwide. In 2017, the company acquired WNT research from Inthera Bioscience SA, a biotechnology company focused on cancer treatment. The acquisition expanded Oryzon Genomics' portfolio to develop new innovative cancer therapies. The field of epigenetics is considered a rising and promising area in the medical industry. Oryzon Genomics has successfully positioned itself as a leading company in this field and continues to work on developing innovative solutions for the treatment of life-threatening diseases. The company remains a company to watch in the biopharmaceutical industry in the coming years. Oryzon Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Oryzon Genomics's Market Capitalization

Oryzon Genomics's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Oryzon Genomics's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Oryzon Genomics's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Oryzon Genomics’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Oryzon Genomics stock

What is the current Oryzon Genomics market capitalization?

The current market capitalization of Oryzon Genomics is 116.16 M EUR.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Oryzon Genomics.

How has the market capitalization of Oryzon Genomics developed in recent years?

The market capitalization of Oryzon Genomics has increased/decreased by -6.79% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Oryzon Genomics?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Oryzon Genomics?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Oryzon Genomics have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Oryzon Genomics pay?

Over the past 12 months, Oryzon Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oryzon Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Oryzon Genomics?

The current dividend yield of Oryzon Genomics is .

When does Oryzon Genomics pay dividends?

Oryzon Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oryzon Genomics?

Oryzon Genomics paid dividends every year for the past 0 years.

What is the dividend of Oryzon Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oryzon Genomics located?

Oryzon Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oryzon Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oryzon Genomics from 9/13/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.

When did Oryzon Genomics pay the last dividend?

The last dividend was paid out on 9/13/2024.

What was the dividend of Oryzon Genomics in the year 2023?

In the year 2023, Oryzon Genomics distributed 0 EUR as dividends.

In which currency does Oryzon Genomics pay out the dividend?

The dividends of Oryzon Genomics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oryzon Genomics

Our stock analysis for Oryzon Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oryzon Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.